Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors
South Plains Oncology Consortium
South Plains Oncology Consortium
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Samsung Medical Center
National Cancer Institute (NCI)
Gustave Roussy, Cancer Campus, Grand Paris